We propose to combine carboplatin, gemcitabine and capecitabine as a palliative treatment for patients with CUP. Programs evaluating the incorporation of newer chemotherapy agents into combinations are reasonable in an attempt to improve outcome in patients with CUP. In addition to anticipated anti-tumor activity, the proposed combination provides a convenient schedule of brief intravenous treatment, the use of the oral agent capecitabine, and a toxicity profile which is expected to be mild, characteristics which are important in palliative treatment programs.